NRG1 and non-small cell lung carcinoma: Indeed, the eNRGy phase I/II basket trial (NCT02912949) and an early access program are evaluating zenocutuzumab in pancreatic, NSCLC, and other solid tumors harboring NRG1 fusion [61].